SRRA Sierra Oncology Inc.

0.6
-0.05  -8%
Previous Close 0.65
Open 0.65
Price To Book 0.53
Market Cap 44,596,374
Shares 74,688,283
Volume 1,093,525
Short Ratio
Av. Daily Volume 1,246,559

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Discontinued following poor efficacy - June 2016
PNT2258
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - cancer
Development suspended - June 2016
PNT2258
Richter's Transformation
Phase 1/2 preliminary data ASCO June 1, 2019 noted stable disease rate of 32%.
SRA737
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Phase 1/2 preliminary data of ORR 30% at ASCO June 1, 2019. 8am.
SRA737 + Low-Dose Gemcitabine
Solid Tumors
Phase 3 trial to be initiated 4Q 2019 with top-line data due 4Q 2021.
Momelotinib - MOMENTUM
Myelofibrosis